U.S. Markets open in 2 hrs 13 mins

CSL Limited (CMXHF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
106.50+0.75 (+0.71%)
At close: 3:20PM EDT
People also watch

CSL Limited

45 Poplar Road
Parkville, VIC 3052
61 3 9389 1911

Full Time Employees

Key Executives

Mr. Paul R. Perreault BA PsychologyCEO, MD & Exec. DirectorN/AN/A60
Mr. David Mark Lamont ACA, BComChief Financial Officer1.85MN/A51
Dr. Andrew Cuthbertson BMedSci, MBBS, Ph.D., FTSE, FAHMS, AOChief Scientific officer & Director of R&DN/AN/A62
Mr. Gregory Boss J.D., BS(Hon)Exec. VP of Legal & Group Gen. CounselN/AN/A56
Ms. Laurie Reed BS (Finance), MS (Organizational Development)Sr. VP of HRN/AN/A53
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


CSL Limited engages in the research, development, manufacture, marketing, and distribution of biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, and internationally. It operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of bleeding disorders, including hemophilia and von Willebrand disease, primary and secondary immunodeficiency’s, hereditary angioedema, neurological disorders, and inherited respiratory diseases. Its products are also used to prevent haemolytic diseases in newborns and infections in solid organ transplant recipients, as well as specific infections; and for urgent warfarin reversal in patients with acute major bleeding, as well as victims of trauma, shocks, and burns. In addition, this segment operates approximately 180 human blood plasma collection centers. Further, it conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and offers influenza vaccines. It also provides in-licensed vaccines and specialty pharmaceuticals; manufactures and markets diagnostics for immunohematology laboratories; and supplies a range of products, including antivenoms and Q fever vaccines. The company was founded in 1916 and is headquartered in Parkville, Australia.

Corporate Governance

CSL Limited’s ISS Governance QualityScore as of September 1, 2017 is 6. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.